Kathleen M. Soucek

Learn More
BACKGROUND AND OBJECTIVES Belatacept is a first-in-class, selective co-stimulation blocker recently approved for the prophylaxis of organ rejection in adult kidney transplant recipients. The objective of this study was to report the pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept. METHODS The pharmacokinetics, pharmacodynamics (CD86(More)
We determined 27 histocompatibility antigens of A, B, and C locus with a standard lymphocyte cytotoxicity test in 125 patients suffering from primary affective disorders, 77 of bipolar type, 24 of unipolar type, and 24 with schizo-affective psychosis. Comparison with a normal control group showed significant increases in the frequencies of antigens Bw40 and(More)
There are conflicting data on the effects of lithium on bone metabolism. Bone formation is known to be reflected by the activity of alkaline phosphatase of the bone tissue. We have found significant differences in mean serum alkaline phosphatase and its bone isoenzyme levels between a group receiving lithium and a control group. In this study increased bone(More)
The objective of this study was to determine the absolute oral bioavailability and disposition of omapatrilat. This single-dose, randomized, crossover study of 20 mg intravenous and 50 mg oral [14C]omapatrilat was conducted in 12 healthy male subjects to determine the disposition and oral bioavailability of omapatrilat, an orally active vasopeptidase(More)